GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Lille, France; Cambridge, MA; January 21, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.
Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2021:
- 137,012 shares
- €512 873.86
During the second half of 2021, total trading was:
- On the buy side: 469,086 shares for a total amount of €1,824,630.43
- On the sell side: 437,124 shares for a total amount of €1,690,993.82
During this same period, the number of trades were:
- On the buy side: 1,402
- On the sell side: 1,389
As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:
- 27, 911 shares
- €769 849,43
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Thanks to its expertise in bringing early-stage assets with high potential to late development and pre-commercialization stages, today GENFIT boasts a growing and diversified pipeline of innovative therapeutic and diagnostic solutions.
Its R&D is focused on three franchises: cholestatic diseases, Acute on Chronic Liver Failure (ACLF) and NASH diagnostics. In its cholestatic diseases franchise, ELATIVE™, a Phase 3 global trial evaluating elafibranor1 in patients with Primary Biliary Cholangitis (PBC) is well underway following a successful Phase 2 clinical trial. Topline data is expected to be announced in early 2023. In 2021, GENFIT signed an exclusive licensing agreement with IPSEN2 to develop, manufacture and commercialize elafibranor in PBC and other indications. GENFIT is also developing GNS5611 in cholangiocarcinoma following the acquisition of exclusive rights in this indication from Genoscience Pharma in 20213. In ACLF, a Phase 1 clinical program with nitazoxanide has been initiated with data expected as early as the third quarter 2022. As part of its diagnostic solutions franchise, the Company entered into an agreement with Labcorp in 2021 to commercialize NASHnext®, powered by GENFIT’s proprietary diagnostic technology NIS4® in identifying at-risk NASH.
GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital. www.genfit.com
GENFIT FORWARD LOOKING STATEMENTS
This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s research and development programs. The use of certain words, including “consider”, “contemplate”, “think”, “aim”, “expect”, “understand”, “should”, “aspire”, “estimate”, “believe”, “wish”, “may”, “could”, “allow”, “seek”, “encourage” or “have confidence” or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, impact of the ongoing COVID-19 pandemic, exchange rate fluctuations and the Company’s continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the French Autorité des Marchés Financiers (“AMF”), including those listed in Chapter 2 “Main Risks and Uncertainties” of the Company’s 2020 Universal Registration Document filed with the AMF on 23 April 2021 under n° D.21-0350, which is available on the Company’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”) including the Company’s 2020 Annual Report on Form 20-F filed with the SEC on April 23, 2021 and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. In addition, even if the Company’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.
CONTACT
GENFIT | Investors
Tel: +33 3 2016 4000 | investors@genfit.com
PRESS RELATIONS | Media
Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com
APPENDIX
H2 2021
| Buy side | Sell side | |||||
| Date | Number of executions | Number of shares | Traded amounts in EUR | Number of executions | Number of shares | Traded amounts in EUR |
| TOTAL | 1 402 | 469 086 | 1 824 630,43 | 1 389 | 437 124 | 1 690 993,82 |
| 01/07/2021 | 6 | 1838 | 5 927,40 | 2 | 996 | 3 231,01 |
| 02/07/2021 | 1 | 1 | 3,27 | 8 | 3006 | 9 867,79 |
| 05/07/2021 | 10 | 6251 | 21 381,61 | 35 | 19412 | 66 280,93 |
| 06/07/2021 | 14 | 5903 | 20 275,97 | 11 | 1554 | 5 370,26 |
| 07/07/2021 | 18 | 7366 | 24 771,90 | 8 | 3386 | 11 647,61 |
| 08/07/2021 | 5 | 1922 | 6 276,40 | 1 | 1 | 3,31 |
| 09/07/2021 | 2 | 101 | 331,46 | 7 | 1922 | 6 314,77 |
| 12/07/2021 | 13 | 3209 | 10 423,77 | 1 | 1 | 3,29 |
| 13/07/2021 | 5 | 1547 | 4 940,57 | 9 | 1229 | 3 953,58 |
| 14/07/2021 | 3 | 637 | 2 039,68 | 6 | 984 | 3 199,06 |
| 15/07/2021 | 7 | 2788 | 8 874,25 | 10 | 2024 | 6 455,01 |
| 16/07/2021 | 9 | 2581 | 8 116,81 | 1 | 1 | 3,15 |
| 19/07/2021 | 12 | 2788 | 8 742,57 | 1 | 1 | 3,17 |
| 20/07/2021 | 4 | 1200 | 3 749,35 | 8 | 2113 | 6 625,59 |
| 21/07/2021 | 2 | 615 | 2 018,35 | 13 | 6462 | 20 919,52 |
| 22/07/2021 | 4 | 1294 | 4 205,50 | 4 | 671 | 2 203,53 |
| 23/07/2021 | 11 | 2888 | 9 620,97 | 15 | 3414 | 11 381,57 |
| 26/07/2021 | 10 | 2603 | 8 518,78 | 3 | 633 | 2 082,61 |
| 27/07/2021 | 4 | 730 | 2 333,11 | 1 | 1 | 3,23 |
| 28/07/2021 | 1 | 1 | 3,24 | 15 | 2709 | 8 881,56 |
| 29/07/2021 | 8 | 1452 | 4 816,39 | 3 | 775 | 2 597,77 |
| 30/07/2021 | 3 | 678 | 2 237,45 | 4 | 1355 | 4 517,58 |
| 02/08/2021 | 9 | 3096 | 10 516,69 | 20 | 6727 | 22 839,93 |
| 03/08/2021 | 2 | 675 | 2 282,89 | 2 | 675 | 2 307,15 |
| 04/08/2021 | 1 | 1 | 3,36 | 1 | 1 | 3,36 |
| 05/08/2021 | 11 | 1759 | 5 879,14 | 1 | 1 | 3,36 |
| 06/08/2021 | 5 | 1045 | 3 460,29 | 1 | 1 | 3,35 |
| 09/08/2021 | 3 | 1310 | 4 304,05 | 7 | 1310 | 4 330,23 |
| 10/08/2021 | 4 | 1303 | 4 247,46 | 4 | 540 | 1 793,88 |
| 11/08/2021 | 1 | 1 | 3,25 | 3 | 1303 | 4 273,43 |
| 12/08/2021 | 1 | 1 | 3,25 | 8 | 2264 | 7 602,81 |
| 13/08/2021 | 1 | 1 | 3,31 | 1 | 1 | 3,31 |
| 16/08/2021 | 1 | 1 | 3,28 | 1 | 1 | 3,28 |
| 17/08/2021 | 1 | 1 | 3,26 | 1 | 1 | 3,26 |
| 18/08/2021 | 2 | 1001 | 3 353,30 | 13 | 5675 | 19 190,25 |
| 19/08/2021 | 3 | 2001 | 6 495,29 | 1 | 1 | 3,29 |
| 20/08/2021 | 1 | 1 | 3,28 | 1 | 1 | 3,28 |
| 23/08/2021 | 4 | 1001 | 3 291,30 | 1 | 1 | 3,30 |
| 24/08/2021 | 5 | 2002 | 6 566,53 | 8 | 4001 | 13 227,28 |
| 25/08/2021 | 12 | 1510 | 4 996,89 | 13 | 2035 | 6 748,11 |
| 26/08/2021 | 6 | 863 | 2 823,78 | 5 | 596 | 1 963,66 |
| 27/08/2021 | 5 | 1124 | 3 663,41 | 11 | 1391 | 4 556,31 |
| 30/08/2021 | 4 | 287 | 941,92 | 3 | 327 | 1 079,72 |
| 31/08/2021 | 25 | 5200 | 19 097,51 | 65 | 11300 | 40 558,11 |
| 01/09/2021 | 28 | 4322 | 15 439,73 | 28 | 5752 | 21 071,16 |
| 02/09/2021 | 10 | 1648 | 5 900,61 | 18 | 1751 | 6 310,35 |
| 03/09/2021 | 10 | 1466 | 5 230,00 | 9 | 1163 | 4 181,66 |
| 06/09/2021 | 7 | 935 | 3 359,48 | 6 | 1180 | 4 250,36 |
| 07/09/2021 | 10 | 1435 | 5 033,09 | 2 | 473 | 1 675,67 |
| 08/09/2021 | 9 | 1318 | 4 526,76 | 3 | 657 | 2 264,14 |
| 09/09/2021 | 3 | 522 | 1 762,27 | 10 | 1672 | 5 772,10 |
| 10/09/2021 | 15 | 1436 | 4 931,66 | 1 | 1 | 3,45 |
| 13/09/2021 | 7 | 1082 | 3 613,50 | 4 | 480 | 1 608,11 |
| 14/09/2021 | 6 | 782 | 2 598,61 | 3 | 246 | 826,56 |
| 15/09/2021 | 6 | 861 | 2 817,28 | 5 | 594 | 1 957,11 |
| 16/09/2021 | 1 | 1 | 3,27 | 8 | 856 | 2 831,12 |
| 17/09/2021 | 3 | 469 | 1 557,12 | 4 | 469 | 1 571,16 |
| 20/09/2021 | 9 | 1283 | 4 201,89 | 3 | 479 | 1 577,41 |
| 21/09/2021 | 9 | 920 | 2 970,21 | 1 | 1 | 3,25 |
| 22/09/2021 | 6 | 1177 | 3 814,10 | 7 | 2353 | 7 701,95 |
| 23/09/2021 | 12 | 1877 | 6 223,17 | 10 | 2183 | 7 279,89 |
| 24/09/2021 | 4 | 515 | 1 681,98 | 10 | 2103 | 7 025,63 |
| 27/09/2021 | 17 | 3045 | 10 187,52 | 14 | 3402 | 11 466,57 |
| 28/09/2021 | 4 | 969 | 3 242,23 | 2 | 21 | 70,52 |
| 29/09/2021 | 4 | 479 | 1 571,96 | 3 | 258 | 847,80 |
| 30/09/2021 | 4 | 772 | 2 521,39 | 4 | 524 | 1 722,00 |
| 01/10/2021 | 5 | 663 | 2 173,13 | 8 | 1325 | 4 374,97 |
| 04/10/2021 | 7 | 1976 | 6 429,90 | 1 | 1 | 3,25 |
| 05/10/2021 | 1 | 1 | 3,25 | 1 | 1 | 3,25 |
| 06/10/2021 | 7 | 1776 | 5 749,14 | 2 | 446 | 1 453,97 |
| 07/10/2021 | 1 | 1 | 3,24 | 2 | 50 | 162,00 |
| 08/10/2021 | 2 | 417 | 1 338,58 | 1 | 1 | 3,22 |
| 11/10/2021 | 3 | 948 | 3 014,64 | 2 | 425 | 1 361,68 |
| 12/10/2021 | 5 | 541 | 1 731,20 | 6 | 2003 | 6 453,80 |
| 13/10/2021 | 2 | 456 | 1 454,66 | 5 | 1737 | 5 635,67 |
| 14/10/2021 | 6 | 1282 | 4 149,56 | 5 | 493 | 1 601,10 |
| 15/10/2021 | 5 | 418 | 1 341,78 | 2 | 418 | 1 357,63 |
| 18/10/2021 | 1 | 1 | 3,24 | 1 | 1 | 3,24 |
| 19/10/2021 | 5 | 287 | 915,54 | 1 | 1 | 3,20 |
| 20/10/2021 | 1 | 1 | 3,22 | 1 | 1 | 3,22 |
| 21/10/2021 | 1 | 1 | 3,22 | 1 | 1 | 3,22 |
| 22/10/2021 | 4 | 662 | 2 132,33 | 1 | 1 | 3,25 |
| 25/10/2021 | 4 | 692 | 2 207,66 | 1 | 1 | 3,25 |
| 26/10/2021 | 3 | 500 | 1 589,50 | 1 | 250 | 797,50 |
| 27/10/2021 | 10 | 1702 | 5 333,70 | 1 | 1 | 3,16 |
| 28/10/2021 | 13 | 2963 | 9 049,62 | 14 | 2076 | 6 311,24 |
| 29/10/2021 | 3 | 624 | 1 899,97 | 11 | 2574 | 7 929,44 |
| 01/11/2021 | 2 | 375 | 1 182,68 | 12 | 1588 | 4 991,89 |
| 02/11/2021 | 7 | 1457 | 4 557,43 | 12 | 831 | 2 614,68 |
| 03/11/2021 | 40 | 7282 | 23 463,05 | 52 | 9135 | 29 608,83 |
| 04/11/2021 | 14 | 2969 | 9 343,12 | 10 | 2123 | 6 722,38 |
| 05/11/2021 | 9 | 1655 | 5 151,86 | 11 | 1757 | 5 504,87 |
| 08/11/2021 | 6 | 1176 | 3 661,62 | 16 | 1520 | 4 788,58 |
| 09/11/2021 | 12 | 1899 | 6 008,83 | 10 | 2805 | 8 956,42 |
| 10/11/2021 | 10 | 1472 | 4 672,94 | 7 | 976 | 3 120,04 |
| 11/11/2021 | 5 | 288 | 914,69 | 1 | 1 | 3,18 |
| 12/11/2021 | 4 | 468 | 1 468,92 | 3 | 257 | 821,33 |
| 15/11/2021 | 2 | 312 | 978,44 | 2 | 312 | 984,66 |
| 16/11/2021 | 6 | 671 | 2 092,38 | 1 | 1 | 3,13 |
| 17/11/2021 | 4 | 288 | 889,92 | 6 | 611 | 1 910,67 |
| 18/11/2021 | 5 | 1468 | 4 529,18 | 1 | 1 | 3,14 |
| 19/11/2021 | 21 | 4493 | 14 438,30 | 29 | 6362 | 20 445,06 |
| 22/11/2021 | 13 | 2504 | 7 835,33 | 4 | 769 | 2 428,38 |
| 23/11/2021 | 3 | 1172 | 3 614,21 | |||
| 24/11/2021 | 3 | 878 | 2 673,75 | 3 | 418 | 1 279,09 |
| 25/11/2021 | 5 | 1209 | 3 689,89 | 6 | 842 | 2 592,53 |
| 26/11/2021 | 14 | 3230 | 9 616,14 | 8 | 1489 | 4 422,56 |
| 29/11/2021 | 1 | 1 | 2,98 | 3 | 474 | 1 421,98 |
| 30/11/2021 | 6 | 1358 | 4 021,38 | 1 | 1 | 3,00 |
| 01/12/2021 | 5 | 474 | 1 412,47 | 4 | 1223 | 3 650,20 |
| 02/12/2021 | 24 | 2033 | 6 009,83 | 1 | 1 | 2,97 |
| 03/12/2021 | 11 | 2248 | 6 526,77 | 3 | 871 | 2 547,02 |
| 06/12/2021 | 12 | 4419 | 12 446,10 | 15 | 3196 | 9 060,38 |
| 07/12/2021 | 18 | 5162 | 14 387,96 | 11 | 2196 | 6 134,58 |
| 08/12/2021 | 16 | 3822 | 10 655,28 | 16 | 4990 | 13 985,97 |
| 09/12/2021 | 6 | 1018 | 2 842,83 | 1 | 1 | 2,80 |
| 10/12/2021 | 8 | 925 | 2 557,53 | 1 | 1 | 2,80 |
| 13/12/2021 | 7 | 2541 | 7 393,19 | 29 | 8590 | 25 035,24 |
| 14/12/2021 | 4 | 1050 | 3 092,28 | 12 | 3266 | 9 724,74 |
| 15/12/2021 | 11 | 3647 | 10 939,66 | 9 | 2672 | 8 094,70 |
| 16/12/2021 | 5 | 383 | 1 145,17 | 4 | 885 | 2 653,79 |
| 17/12/2021 | 93 | 15001 | 63 380,90 | 119 | 22550 | 98 088,20 |
| 20/12/2021 | 54 | 7001 | 31 287,98 | 68 | 8201 | 36 836,38 |
| 21/12/2021 | 62 | 12301 | 56 420,66 | 62 | 12301 | 56 713,66 |
| 22/12/2021 | 28 | 6801 | 30 348,50 | 37 | 8501 | 38 174,50 |
| 23/12/2021 | 35 | 10001 | 46 254,64 | 42 | 11202 | 52 060,34 |
| 24/12/2021 | 11 | 3001 | 13 789,69 | 8 | 2001 | 9 244,69 |
| 27/12/2021 | 96 | 73295 | 321 612,05 | 24 | 19145 | 85 632,92 |
| 28/12/2021 | 41 | 36097 | 151 338,73 | 45 | 37570 | 158 643,33 |
| 29/12/2021 | 39 | 39629 | 166 774,13 | 47 | 40699 | 172 426,59 |
| 30/12/2021 | 43 | 39268 | 165 308,75 | 33 | 41884 | 177 316,00 |
| 31/12/2021 | 49 | 46541 | 198 631,12 | 40 | 43677 | 186 799,85 |
1 Elafibranor and GNS561 are investigational compounds that have not been reviewed nor been approved by a regulatory authority
2 With the exception of China, Hong Kong, Taiwan, and Macau where Terns Pharmaceuticals holds the exclusive license to develop and commercialize elafibranor
3 Agreement includes commercialization and development in the United States, Canada and Europe, including the United Kingdom and Switzerland
GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com
Attachment
